Investing.com -- Recursion Pharmaceuticals (NASDAQ:RXRX) stock tumbled 12% Wednesday morning after regulatory filings revealed that NVIDIA (NASDAQ:NVDA) had completely divested its stake in the ...

The Utah Mammoth announced today that the public side of the practice and training facility in Sandy, Utah will begin offering a range of programming for people of all ages and experience levels on ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

Learn how to use advanced techniques like short-circuiting, parallel execution, virtual threads, and stream gatherers to maximize Java stream performance. My recent Java Stream API tutorial introduced ...

What does it take to become the best at something? The answer may not lie in early childhood excellence or in lifelong, laser-focused dedication. Instead the path to becoming exceptional at a skill ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Embark on a fulfilling pharmacy career with our Pharmacy Technician Training Program. Our 16-week program allows you to gain the skills required for safe patient care. The self-paced format ensures ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...